Updated Sep 2, 2026
/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline/Trump and Rubio seal Venezuela oil deal covering 65 billion barrels across 17 fields/Bond rout gathers pace as borrowing costs hit multi-decade highs/Van Jones calls El-Sayed's total Israel arms embargo 'insane,' cites Obama legacy on defense/Memecoin buys on Robinhood Wallet and Fomo coded as "digital media," sidestepping card-network crypto rules/Caring Brands (CABR) Closes $4.6 Million Initial Series B Preferred Stock Private Placement/Sanmar Group takes majority stake in AltEons Energy to back 1.5GW India pipeline

J&J Bets on Cancer Over Obesity as FDA Clears GSK Antibiotic for Drug-Resistant Infections

Johnson & Johnson will not pursue the obesity drug market, Chief Executive Joaquin Duato said, opting instead to build the company into what he described as the world's leading cancer company. The move sets J&J apart from rivals scrambling…

By Julian Merrick2 min readJNJLLY
Share